Corona Remedies manufactures pharmaceutical products with a market cap of ₹13,079 Cr. Quarterly revenues range ₹340–₹420 Cr with operating margins of 20.9% and ROE of 32%.
Valuation: PE 65.71 leaves minimal buffer for earnings disappointment.
Margin compression: Operating margin fell from 24.29% (Dec 2025) to 17.56% (Mar 2026)—verify cause.
Revenue volatile: ₹361 (Sep) → ₹342 (Dec) → ₹353 (Mar) → ₹422 (Jun) Cr; verify if operational, seasonal, or demand-driven.
FII 3.63%, institutional participation low—verify if sector-wide or company-specific.
Generated analysis · source review pending
Revenue up 17% from Sep 2025 (₹361 Cr) to Jun 2026 (₹422 Cr); profit up 15% (₹52 → ₹60 Cr)—highest in four quarters.
Operating margin recovered from 17.56% (Mar 2026) to 22.05% (Jun 2026), signaling operational improvement.
ROE 32.04% indicates profitable capital deployment—verify if reinvested in capacity or market expansion.
Dividend paid Jun 2026 alongside ₹60.1 Cr profit signals management confidence in cash generation.
Generated analysis · source review pending
194 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Consolidated figures
| Ratio | Mar 2023 | Mar 2026 |
|---|---|---|
| Margins | ||
| Gross margin % | 76.1% | 81.4% |
| EBITDA margin % | 17.2% | 20.9% |
| EBIT margin % | 15% | 18.2% |
| PAT margin % | 9.6% | 13.2% |
| Working capital | ||
| Receivable days | 36 | 38 |
| Inventory days | 182 | 175 |
| Payable days | — | 206 |
| NWC days | — | 7 |
| Leverage | ||
| Current ratio | 2.12 | 0.96 |
| Debt to EBITDA | 0.02 | 0.49 |
| Debt to equity | 0.01 | 0.19 |
| Interest coverage | 32.6 | 38.2 |
| Asset turnover | 1.49 | 1.16 |
| Return ratios | ||
| Return on assets % | 14.3% | 15.4% |
| Return on capital employed % | 30.4% | 40.9% |
| Return on equity % | 20.8% | 24.8% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
| Holder (%) | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| 69% | 69% | 69% | 69% | |
| 1.04% | 1.84% | 2.25% | 3.63% | |
| 3.65% | 6.76% | 7.02% | 12.9% | |
| Government | 0% | 0% | 0% | 0% |
| 26.31% | 22.4% | 21.73% | 14.47% | |
| No. of shareholders | 1,59,545 | 31,035 | 19,609 | 20,185 |
Promoter holding up 0 percentage points since Sep 2025.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 10 Sept 2026 | SEPIA INVESTMENTS LIMITED | Bulk | BSE | Sell | 24,85,476 | ₹2,050.32 | ₹509.60 Cr |
| 10 Sept 2026 | SBI MUTUAL FUND | Bulk | BSE | Buy | 8,60,000 | ₹2,050.00 | ₹176.30 Cr |
| 10 Sept 2026 | SBI MUTUAL FUND | Bulk | BSE | Buy | 6,80,000 | ₹2,050.00 | ₹139.40 Cr |
| 10 Sept 2026 | AMUNDI FUNDS ASIA EQUITY CONCENTRATED | Bulk | BSE | Buy | 3,12,000 | ₹2,050.00 | ₹63.96 Cr |
| 17 Jun 2026 | SEPIA INVESTMENTS LIMITED | Block | NSE | Sell | 43,28,943 | ₹1,730.00 | ₹748.91 Cr |
| 17 Jun 2026 | SEPIA INVESTMENTS LIMITED | Bulk | NSE | Sell | 43,28,943 | ₹1,730.00 | ₹748.91 Cr |
| 17 Jun 2026 | HDFC MUTUAL FUND | Block | NSE | Buy | 24,50,000 | ₹1,730.00 | ₹423.85 Cr |
| 17 Jun 2026 | HDFC MUTUAL FUND | Bulk | NSE | Buy | 23,33,333 | ₹1,730.00 | ₹403.67 Cr |
| 17 Jun 2026 | ADITYA BIRLA SUN LIFE MUTUAL FUND | Block | NSE | Buy | 4,90,000 | ₹1,730.00 | ₹84.77 Cr |
| 17 Jun 2026 | ADITYA BIRLA SUN LIFE MUTUAL FUND | Bulk | NSE | Buy | 4,62,035 | ₹1,730.00 | ₹79.93 Cr |
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM | ₹1,61,325 Cr | ₹1,76,123 Cr | ₹15,723 Cr | ₹5,191 Cr | 32.6% | ₹2,181 Cr | 15.3% | 14.5% | 27.1% | 163 |
| Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE | ₹1,14,284 Cr | ₹1,26,053 Cr | ₹28,592 Cr | ₹8,316 Cr | 31.2% | ₹4,513 Cr | 18.9% | 23.4% | 19.7% | 212 |
| Laurus Labs LimitedLAURUSLABSLAURUSLABS | ₹1,07,176 Cr | ₹1,09,573 Cr | ₹7,270 Cr | ₹2,034 Cr | 26.1% | ₹1,093 Cr | 13.1% | 21.3% | 18.2% | 263 |
| Mankind Pharma LimitedMANKINDMANKIND | ₹1,04,696 Cr | ₹1,11,007 Cr | ₹14,738 Cr | ₹3,827 Cr | 25.3% | ₹2,068 Cr | 13.6% | 14.2% | 12.5% | 117 |
| Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA | ₹97,389 Cr | ₹1,05,065 Cr | ₹34,935 Cr | ₹7,085 Cr | 20.3% | ₹3,713 Cr | 10.4% | 14.7% | 9.9% | 252 |
| Lupin LimitedLUPINLUPIN | ₹92,866 Cr | ₹98,777 Cr | ₹29,967 Cr | ₹9,538 Cr | 31.5% | ₹5,529 Cr | 19.2% | 34.2% | 26.9% | 181 |
| Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK | ₹65,781 Cr | ₹65,781 Cr | ₹17,737 Cr | ₹4,797 Cr | 26.9% | ₹1,496 Cr | 8% | 37.8% | 0% | 83 |
| Alkem Laboratories LimitedALKEMALKEM | ₹62,431 Cr | ₹64,055 Cr | ₹15,081 Cr | ₹3,032 Cr | 20.4% | ₹2,158 Cr | 16% | 21.5% | 17.8% | 152 |
| Biocon LimitedBIOCONBIOCON | ₹60,413 Cr | ₹75,238 Cr | ₹17,321 Cr | ₹3,536 Cr | 20.4% | ₹495 Cr | 2.2% | 3.9% | 1.4% | 85 |
| Abbott India LimitedABBOTINDIAABBOTINDIA | ₹56,901 Cr | — | ₹4,310 Cr | ₹921 Cr | 27.3% | ₹691 Cr | 22.4% | 44.1% | 34.5% | 110 |
| Ipca Laboratories LimitedIPCALABIPCALAB | ₹49,299 Cr | ₹50,003 Cr | ₹10,126 Cr | ₹2,232 Cr | 20.5% | ₹1,310 Cr | 12.3% | 17.8% | 15.2% | 308 |
| Gland Pharma LimitedGLANDGLAND | ₹47,428 Cr | ₹47,671 Cr | ₹6,725 Cr | ₹1,751 Cr | 25.3% | ₹1,129 Cr | 16% | 14.8% | 10.5% | 255 |
Documents link to external sources (exchange filings, company investor pages).
Closure of Trading Window
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Clarification On Movement In Volume
Clarification sought from Corona Remedies Ltd
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
| Date | Category | Subject | Filing |
|---|---|---|---|
| 30 Sept 2026, 7:16 pm | Company Update Credit Rating | Announcement under Regulation 30 (LODR)-Credit Rating | |
| 28 Sept 2026, 5:03 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window | |
| 19 Sept 2026, 3:42 pm | Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | |
| 19 Sept 2026, 3:14 pm | Insider Trading / SAST Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 | |
| 18 Sept 2026, 2:56 pm | Company Update Analyst / Investor Meet | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | |
| 10 Sept 2026, 12:08 pm | Company Update General | Clarification On Movement In Volume | |
| 10 Sept 2026, 11:08 am | Company Update Clarification | Clarification sought from Corona Remedies Ltd | — |
| 20 Aug 2026, 5:18 pm | Company Update Analyst / Investor Meet | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
8 schemes · 4 fund houses
| Shares | ||||||
|---|---|---|---|---|---|---|
| Portfolio of Kotak Business Cycle Fund | Kotak Mahindra Mutual Fund | 1.62 L | 33.19 | 0.95% | 0.264% | -0 |
| Portfolio of Kotak Healthcare Fund | Kotak Mahindra Mutual Fund | 60,000 | 12.3 | 1.6% | 0.098% | -0 |
| Portfolio of Kotak Consumption Fund | Kotak Mahindra Mutual Fund | 54,877 | 11.25 | 0.65% | 0.09% | -3,615 |
| Equity Savings Fund | Axis Mutual Fund | 39,380 | 8.07 | 0.91% | 0.064% | -0 |
| (Investment Manager for Motilal Oswal Mutual Fund) | Motilal Oswal Mutual Fund | 16,105 | 3.3 | 0.13% | 0.026% | -352 |
| (Investment Manager for Motilal Oswal Mutual Fund) | Motilal Oswal Mutual Fund | 168 | 0.03 | 0.08% | 0% | -0 |
| IB18-Groww Nifty Total Market Index Fund | Groww Mutual Fund | 110 | 0.02 | 0.01% | 0% | +1 |
| (Investment Manager for Motilal Oswal Mutual Fund) | Motilal Oswal Mutual Fund | 18 | 0 | 0.01% | 0% | -0 |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2023 | Mar 2026 |
|---|---|---|
| 884 | 1,403 | |
| COGS | 211 | 261 |
| Gross profit | 673 | 1,142 |
| 521 | 849 | |
| 152 | 293 | |
| OPM % | 17.2% | 20.9% |
| Depreciation | 20 | 38 |
| Interest | 4 | 7 |
| 7 | -8 | |
| Profit before tax | 111 | 240 |
| Tax | 26 | 55 |
| Tax % | 23.4% | 23% |
| 85 | 185 | |
| PAT margin % | 9.6% | 13.2% |
| EPS (₹) | 14.6 | 30.3 |
| EPS adjusted (₹) | — | 30.3 |
| 0% | 33% | |
| Annual report | — | Annual report for Mar 2026 |
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 61 | 61 | 61 | 61 |
| Reserves | 347 | 419 | 545 | 686 |
| 2 | 134 | 63 | 143 | |
| 184 | 216 | 261 | 315 | |
| Total equity & liabilities | 595 | 831 | 930 | 1,205 |
| 185 | 384 | 370 | 554 | |
| CWIP | 65 | 121 | 186 | 143 |
| Investments | 6 | 0 | 0 | 26 |
| 340 | 326 | 374 | 482 | |
| Total assets | 595 | 831 | 930 | 1,205 |
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 103 | 157 | 190 | 229 | |
| -50 | -267 | -84 | -256 | |
| -45 | 99 | -107 | 25 | |
| Net cash flow | 8 | -11 | 0 | -1 |
| Free cash flow | — | — | — | 55 |
| CFO / Operating profit % | 67.4% | — | — | 78.2% |